Immunai

Immunai is a biotech company focused on mapping the human immune system and developing new immunotherapies against cancer and autoimmune diseases. The company utilizes cutting-edge genomics and machine learning technology to decode immunity and discover novel mechanisms for developing better therapeutics. Immunai's approach combines single-cell immunonics with advanced computational methods to elucidate critical biology and power drug discovery.

The company's core technology involves multiomic immune profiling and high-throughput sequencing approaches to measure cellular responses. This allows Immunai to study immune cell variations across patient cohorts and understand host-pathogen interactions. By applying machine learning and data science to analyze this complex immune system data, Immunai aims to accelerate the typically years-long and billion-dollar process of drug discovery.

Immunai's scientific approach was inspired by groundbreaking work from its co-founders that demonstrated how single-cell immune profiling from just six patients could reveal previously unknown mechanisms of action for cancer immunotherapy drugs. The company has built a diverse, multidisciplinary team combining expertise in machine learning, Big Data, and immunology to pursue its vision of revolutionizing drug development.

In May 2021, Immunai acquired Nebion, a provider of curated genomic data and analysis tools, to expand its capabilities. The company's leadership includes individuals with backgrounds spanning academia, biotech, and technology sectors, positioning Immunai at the intersection of computational methods and cutting-edge biology.